This issue, one of our largest, is devoted to active surveillance. There are multiple reasons for the extensive set of interviews contained in this issue. First, most men diagnosed with prostate cancer have an indolent cancer that all to often gets overtreated; therefore, any approach that reduces the incidence of overtreatment deserves attention. Active surveillance is the most successful approach. Second, the process of refining active surveillance is leading to major insights about the underlying molecular alterations that fuel aggression in prostate cancer. Finally, active surveillance is an excellent topic to help you gain insights into how science is done at the highest levels.

View November's publication